Celldex Therapeutics, Inc (CLDX) Dividend History

Company News

• Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

  Celldex Therapeutics presented positive preclinical data for its bispecific antibody CDX-622, which targets TSLP and SCF to reduce inflammation and fibrosis. The data showed CDX-622 inhibits TSLP and SCF-dependent activities, and a Phase 1 study in healthy volunteers is ongoing.

  GlobeNewswire Inc.
• Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

  Celldex Therapeutics announced positive data from Phase 2 studies of its drug barzolvolimab in patients with chronic urticaria, demonstrating improved disease control and quality of life.

  GlobeNewswire Inc.
• Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight

  The chronic spontaneous urticaria market is expected to grow due to increased disease prevalence, improved diagnosis, and the launch of new therapies. Key companies working on innovative treatments include Novartis, Sanofi, Regeneron, Celldex Therapeutics, Jasper Therapeutics, and others.

  GlobeNewswire Inc.

  Featured Companies: JSPR REGN
• Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

  Celldex Therapeutics has initiated a Phase 2 study of barzolvolimab, a mast cell depleting agent, for the treatment of moderate to severe atopic dermatitis. The study aims to evaluate the efficacy and safety of barzolvolimab in this patient population.

  GlobeNewswire Inc.
• Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight

  The urticaria pipeline is rapidly expanding, with over 20 leading companies developing 25+ new treatments to address the rising prevalence of the condition. Advances in biologic therapies and a strong R&D pipeline are driving progress, while improved healthcare infrastructure and digital innovations enhance patient access and outcomes.

  GlobeNewswire Inc.

  Featured Companies: ENTA KNSA REGN